Form 4: Candel Therapeutics Director Christopher Martell Increases Stake Through Registered Direct Offering

Candel Therapeutics, Inc. Director and 10% owner Christopher Martell acquired 111,349 shares of common stock at $4.67 per share through a registered direct offering.

Summary

• Christopher Martell, a Director and 10% owner of Candel Therapeutics, Inc. (CADL), acquired 111,349 shares of common stock.
• The acquisition occurred on June 25, 2025, at a price of $4.67 per share.
• These shares were acquired from the Issuer as part of a registered direct offering, pursuant to a Securities Purchase Agreement dated June 23, 2025.
• Following this transaction, Mr. Martell's beneficial ownership includes 111,349 shares held by his spouse, 152,000 shares held by GTAM1 2012 LLC, and 283,514 shares held by GTAM1 2012 ADV LLC, totaling 546,863 shares.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director and 10% owner suggests confidence in the company's future prospects, which is generally viewed positively by the market.

Positives

• A Director and 10% owner, Christopher Martell, increased his beneficial ownership in Candel Therapeutics, Inc. by acquiring 111,349 shares, which can signal confidence in the company's future prospects.
• The acquisition was part of a registered direct offering, which typically provides capital to the company.

Future Outlook

This Form 4 filing is a transactional report and does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

This document is an SEC Form 4, which reports changes in beneficial ownership by company insiders. It provides specific details on an individual's stock transactions and holdings, rather than broad industry trends or competitive analysis.

Related Party Transactions

• Christopher Martell, a director and 10% owner, acquired shares directly from Candel Therapeutics, Inc. as part of a registered direct offering.
• Shares are indirectly held by GTAM1 2012 LLC and GTAM1 2012 ADV LLC, entities for which the reporting person serves as trustee or manager, respectively, and disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: May view the insider acquisition as a positive signal of management confidence. The direct offering implies potential dilution if new shares were issued, but also capital infusion for the company.
• Company: Received capital from the registered direct offering.

Key Dates

Keywords

Candel Therapeutics, CADL, Form 4, insider trading, beneficial ownership, stock acquisition, direct offering, Christopher Martell